Insilico's AI-designed drug lowered predicted biological age three to four years in a 42-patient trial
Six aging clocks built independently at Harvard, Oxford, Beijing, and Insilico all read patients on rentosertib as three to four years biologically younger by week four, one as much as six. The Nature Biotechnology analysis covers an AI-designed TNIK inhibitor drawn from a 42-patient study and now in Phase III for pulmonary fibrosis. What carries weight is the agreement between models that share no features or training data, plus a dosing split: 30 mg twice daily shifted predicted age furthest, while 60 mg once daily did more for lung function. The small sample and absence of healthy volunteers keep this short of proof, but a longevity endpoint now rides inside a real late-stage drug program.
Source: the-decoder.com ↗
What convinces me is not the size of the effect but the agreement, because these models share neither their features nor their training data.
Why this matters
- → Six independent aging clocks agree on biological rejuvenation — rare signal-to-noise ratio.
- → Longevity endpoint now embedded inside late-stage drug approval pathway.
- → AI-designed molecule targets aging mechanism in humans for first time at scale.